Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TST001 |
Synonyms | |
Therapy Description |
TST001 is a humanized monoclonal antibody that targets Claudin 18 isoform 2 (CLDN 18.2), which potentially induces complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis against CLDN18.2 expressing tumor cells (AACR; 2020. Abstract nr: 5183/9). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TST001 | TST-001|TST 001 | CLDN18.2 Antibody 19 | TST001 is a humanized monoclonal antibody that targets Claudin 18 isoform 2 (CLDN 18.2), which potentially induces complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis against CLDN18.2 expressing tumor cells (AACR; 2020. Abstract nr: 5183/9). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04396821 | Phase I | TST001 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |